Skip to content

Visual Perceptual Learning for the Treatment of Visual Field Defect

Efficacy and Safety of Visual Perceptual Learning Using the Nunap Vision for Improvement of Visual Field Defect Caused by Brain Damage: Multi Center, Superiority Prove, Double-blind, Randomized, Confirmatory Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04102605
Acronym
VIVID2
Enrollment
80
Registered
2019-09-25
Start date
2019-10-17
Completion date
2021-05-31
Last updated
2021-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemianopsia, Homonymous, Visual Fields Hemianopsia

Keywords

Visual field defect, visual perceptual learning, Humphrey visual field

Brief summary

This study evaluates the efficacy of visual perceptual learning for the treatment of visual field defect caused by brain damage. Half of participants will receive visual perceptual training using the Nunap Vision, while the other half will receive sham training using the Nunap Vision-C.

Interventions

DEVICENunap Vision

Participants receive visual perceptual training using the Nunap Vision software

DEVICENunap Vision-C

Participants receive sham training using the Nunap Vision-C software

Sponsors

Nunaps Inc
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age 19-80 years * Brain damage-induced visual field defect * At least 6 months after brain lesion * Minimum of 4 testing locations, where measured threshold ≤ 20dB * Verified visual pathway damage using CT or MRI * K-MMSE(Korean Mini Mental Status Examination) score ≥ 24 * Visual acuity equal or better than 20/40 * Able to use the investigational device * Patient/legally authorized representative has signed the informed consent form

Exclusion criteria

* Unreliable Humphrey visual field test (any of fixation loss, false positive, false negative ≥ 20%) * Complete hemianopsia with sensitivity of the whole hemifield ≤ 3 dB * Epilepsy, photosensitivity, Parkinson's disease * Bilateral visual field defect * Hemispatial neglect * Ophthalmologic disorder that may interfere the trial * Inability to discontinue psychostimulants such as methylphenidate, modafinil, and amphetamine. * Candidate for carotid endarterectomy or stenting * Received ophthalmologic surgery within 3 months, except for the cataract surgery * Pregnant or breast feeding * Participating in other clinical trial * Any other condition that, in the opinion of the investigator, precludes participation in the trial

Design outcomes

Primary

MeasureTime frameDescription
Area of Humphrey visual field where sensitivity increased by equal or more than 6 dB relative to baseline12 weeksImproved regions have luminance sensitivity that increased by equal or more than 6 dB relative to baseline. The improved area ranges between 0 and 972 degree\^2, of which larger area indicates better outcome.

Secondary

MeasureTime frameDescription
Changes in Humphrey visual field mean deviation relative to baseline12 weeksChanges in mean deviation value of whole field or defect field compared with the baseline value. The change of mean deviation ranges between -35 to +35 dB, of which higher value indicates better outcome.
Changes in scores of NEI-VFQ-25(the National Eye Institute Visual Function Questionnaire 25) relative to baseline12 weeksChanges in each components of NEI-VFQ-25 scores relative to baseline. The change of scores ranges between -100 to 100, of which higher value indicates better outcome.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026